Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Stock Information for Epsilon Energy Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Epsilon Energy Ltd.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Six Flags Entertainment Corporation (FUN), Skye Bioscience, Inc. (SKYE), and Stride, Inc. (LRN)
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience to Present Poster at Keystone Obesity Conference
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.